Talazoparib-Enzalutamide Improves Survival in Metastatic CRPC

[ad_1]

(MedPage Today) — SAN FRANCISCO — Adding talazoparib (Talzenna) to enzalutamide (Xtandi) as initial treatment for metastatic castration-resistant prostate cancer (CRPC) prolonged survival, new analyses from the TALAPRO-2 trial indicated.
In…

[ad_2]

Source link : https://www.medpagetoday.com/meetingcoverage/mgucs/114203

Author :

Publish date : 2025-02-13 18:12:27

Copyright for syndicated content belongs to the linked Source.